Comera will develop a differentiated formulation of an Intas product using Comera’s innovative proprietary SQore formulation platform
Intas Pharmaceuticals announced a research collaboration with Comera Life Sciences, to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience.
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera’s innovative proprietary SQore formulation platform. Intas will initially provide research funding with the option to acquire global rights to the formulation through an exclusive license with responsibility for subsequent development and commercialisation.
“We are excited to work with Comera to enhance therapeutic options and access for patients,” said Binish Chudgar, Vice Chairman and MD, Intas Pharmaceuticals. “This collaboration will accelerate our quest to develop innovative, value-added medicines that can make a difference in patients’ lives globally,” he added.
“This collaboration is the latest step in our long-term partnership strategy to leverage our SQore platform and transition from preclinical, early-stage assets to late-stage, marketed products,” said Jeff Hackman, President, CEO and Chairman, Comera. “We look forward to working with Intas and developing a differentiated formulation that will make it easier for patients to use and increase healthcare savings.”
